JW (Cayman) Therapeutics Co. Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG5210T1040
HKD
2.19
0.15 (7.35%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Viva Biotech Holdings
Frontage Holdings Corp.
JOINN Laboratories (China) Co., Ltd.
Kintor Pharmaceutical Ltd.
Jacobio Pharmaceuticals Group Co., Ltd.
Sirnaomics Ltd.
Sinomab Bioscience Ltd.
CanSino Biologics, Inc.
Beijing Lüzhu Biotechnology Co., Ltd.
JW (Cayman) Therapeutics Co. Ltd.
Ascletis Pharma, Inc.

Why is JW (Cayman) Therapeutics Co. Ltd. ?

1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
  • Poor long term growth as Operating profit has grown by an annual rate -2.93% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -227.87
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 23.73%, its profits have risen by 23.9%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is JW (Cayman) Therapeutics Co. Ltd. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
JW (Cayman) Therapeutics Co. Ltd.
23.73%
-0.06
87.20%
Hang Seng Hong Kong
8.25%
0.41
19.93%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
186.40%
EBIT Growth (5y)
-2.93%
EBIT to Interest (avg)
-227.87
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
0.08
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.58
EV to EBIT
-3.12
EV to EBITDA
-3.86
EV to Capital Employed
1.83
EV to Sales
9.19
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-58.81%
ROE (Latest)
-39.94%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
OPERATING CASH FLOW(Y)

Highest at HKD -603.74 MM

OPERATING PROFIT(Q)

Highest at HKD -82.08 MM

RAW MATERIAL COST(Y)

Fallen by -661.44% (YoY

NET SALES(Q)

Highest at HKD 114.23 MM

OPERATING PROFIT MARGIN(Q)

Highest at -71.86 %

PRE-TAX PROFIT(Q)

Highest at HKD -123.17 MM

NET PROFIT(Q)

Highest at HKD -123.17 MM

-5What is not working for the Company
ROCE(HY)

Lowest at -51.56%

CASH AND EQV(HY)

Lowest at HKD 708.67 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.82 times

Here's what is working for JW (Cayman) Therapeutics Co. Ltd.

Operating Profit
Highest at HKD -82.08 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite positive

Operating Profit (HKD MM)

Operating Cash Flow
Highest at HKD -603.74 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Net Sales
Highest at HKD 114.23 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (HKD MM)

Operating Profit Margin
Highest at -71.86 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at HKD -123.17 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Pre-Tax Profit
At HKD -123.17 MM has Grown at 52.69%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit
Highest at HKD -123.17 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (HKD MM)

Raw Material Cost
Fallen by -661.44% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for JW (Cayman) Therapeutics Co. Ltd.

Cash and Eqv
Lowest at HKD 708.67 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio
Lowest at 1.82 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio